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Abstract: Binders of langerin could target vaccines to Lan-
gerhans cells for improved therapeutic effect. Since langerin
has low affinity for monovalent glycan ligands, highly multi-
valent presentation has previously been key for targeting.
Aiming to reduce the amount of ligand required, we rationally
designed molecularly defined high-affinity binders based on
the precise display of glycomimetic ligands (Glc2NTs) on
DNA-PNA scaffolds. Rather than mimicking langerinQs ho-
motrimeric structure with a C3-symmetric scaffold, we devel-
oped readily accessible, easy-to-design bivalent binders. The
method considers the requirements for bridging sugar binding
sites and statistical rebinding as a means to both strengthen the
interactions at single binding sites and amplify the avidity
enhancement provided by chelation. This gave a 1150-fold net
improvement over the affinity of the free ligand and provided
a nanomolar binder (IC50 = 300 nM) for specific internaliza-
tion by langerin-expressing cells.
Introduction
Carbohydrate-protein interactions drive important bio-
logical recognition processes on cell membranes. Typically,
sugar-binding receptors such as the mammalian lectins, which
govern binding of bacteria and viruses to cell membranes,
have only millimolar affinity and display low specificity for
monovalent carbohydrates. To increase affinity and allow
specific interactions to occur at low concentration, nature
takes advantage of concerted carbohydrate-protein interac-
tions among multivalent binding partners.[1] Similarly, multi-
valency is the key tool for the design of compounds that target
multimeric carbohydrate-binding proteins. Impressive results
have been obtained by brute force presentation of hundreds
of glycan ligands on display materials such as polymers,[2]
liposomes,[3] nanoparticles[4] and carbon nanotubes.[5] How-
ever, while this shotgun-type tactic can lead to extremely high
potencies the approach will reveal little information about the
spatial arrangement of binding sites. An alternative approach
relies on multivalent presentation on molecularly and stoi-
chiometrically defined scaffolds such as dendrimers,[6] calix-
arenes,[7] carbohydrates,[8] cyclodextrines,[9] peptides[10] or
DNA.[11]
Two different interaction mechanisms guide the design of
multivalent binding agents, namely the chelate effect and the
statistical rebinding effect. The chelate effect is active when
two or more ligands are able to bridge the carbohydrate
binding sites of a multivalent receptor system. The statistical
rebinding effect takes place when two or more ligands bind to
only one binding site, quickly replacing each other and
leading to reduced apparent off rates (Figure S1).[12] Both
effects can work in concert if distances between binding sites
are small and glycan ligands are densely clustered or
presented on short to medium length flexible scaffolds. The
design criteria are more demanding for low affinity binding
sites that are separated by larger distances (+ 40 c). Flexible
linkers sample a large conformational space and may there-
fore allow both bridging of binding pockets and rebinding.
However, the increase of effective molarity provided by
flexible linkers may not be sufficient to reach the concen-
tration threshold required for bridging two low affinity
binding sites.[13] Suitably designed rigid spacers based on
capsid proteins[14] or DNA[13b] offer a solution to this problem.
DNA-based scaffolds are particularly attractive due to the
ability to combine a small number of component strands into
a wide variety of structures through sequence-programmed
hybridization. As a result, a large number of arrangements
can be screened with relatively little synthetic effort.[15]
DNA-type scaffolds facilitate multivalency-enhanced
binding by providing high effective molarities provided that
the ligands are attached in a distance matching the distance of
binding sites.[13] Molecular dynamics simulations showed that
nicked PNA-DNA complexes provide rotational degrees of
freedom. Bending can occur, albeit at the cost of strain that
can be reduced by incorporating single stranded segments.[15d]
Furthermore, a substantial body of work suggests that the
molecular ruler properties of DNA-type scaffolds are not
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affected by the linkers used by us (meaning that highest
affinities were obtained for complexes presenting the ligands
in a distance that matched the distance between binding sites
on structurally characterized targets).[13b, 15d–i, 16] However, due
to the rigidity of DNA scaffolds statistical rebinding cannot
contribute to the multivalent interactions if ligands are
separated by large distances. Furthermore, chelation-induced
binding enhancements remain low when the strength of the
monovalent interaction is weak.[13, 17]
A viable method to foster interactions with a multivalent
carbohydrate-binding protein is to increase the number of
glycan ligands that simultaneously interact with the multi-
meric receptor system. Three-arm DNA scaffolds have been
optimized for interactions with receptors offering three
binding sites.[18] Such distance-matched multivalent scaffolds
are difficult to design and often the affinity enhancements
remain in the order expected for bivalent interactions. Herein
we propose an alternative approach to rationally improve the
avidity enhancement provided by a nucleic acid scaffold.
In an exemplary study, we sought high affinity binders for
the C-type lectin langerin expressed on Langerhans cells.
Langerin plays an important role in recognizing and internal-
izing pathogens into Langerhans cells which are able to
stimulate T-cell responses through antigen presentation.[19]
Therefore, targeting of langerin has the potential to allow
specific delivery of vaccination agents to Langerhans cells.
The langerin extracellular domain (ECD) forms a trimeric
structure comprised of three carbohydrate recognitions
domains (CRD).[20] Rather than attempting the design of
a C3-symmetrical scaffold that would match the arrangement
of langerinQs sugar binding sites, we present a straightforward
method to enhance the avidity of readily accessible, easy to
design bivalent binders. The method hinges on the positive
correlation between the strength of the monovalent ligand-
receptor interaction and the magnitude of the avidity
enhancement provided by chelation.[17] In this first systematic
study, we use statistical rebinding to improve interactions at
individual sugar binding sites and amplify the x-fold chelate
bivalency enhancement.
Results and Disucssion
Crystal structure analysis showed that the carbohydrate
binding sites of langerin are positioned 42 c apart on the
exposed surface of the trimer (Figure 1A).[20] In solution, the
binding sites will sample the conformational space, however,
at current there are no reports about the minimal and
maximal possible distances accessible by the protein. Langer-
in recognizes a subset of high mannose oligosaccharides,
blood group B trisaccharides and b-glucans containing
glucose, fucose and mannose, respectively.[21] High binding
affinities have been reported for sulphated saccharides.[22]
Potent natural monovalent ligands of langerin are N-acetyl-
Figure 1. A) Crystal structure of the trimeric langerin extracellular domain (PDB ID: 3kqg) with Ca2+ ions (green) embedded in the binding sites,
which are 42 b apart. B) Structures of Glc2NTs ligand and Glc2NTs-PNA conjugates. C) Structures of TriGlc2NTs ligand and TriGlc2NTs-PNA
conjugates. D) Hybridization of modified (orange, red) and unmodified (black) peptide nucleic acid (PNA) oligomers with DNA templates affords
bivalent PNA-DNA complexes displaying ligands (yellow) in different distances. PNA 1: tcatcgccttcta, PNA 2: acct*atggacttt, PNA 3: actt*actt-
cacgc, PNA 4: atgctacgtt*gac, PNA 5: aactcctact*cct, PNA 6: atacat*ccaacac, PNA 7: tcat*tcact*cggc, PNA 8: acct#atggacttt, PNA 9: atgc-
tacgtt#gac (* =Glc2NTs modification; # =TriGlc2NTs modification).
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glucoseamine (KD& 4 mM) and mannose (KD& 5 mM),[22c,23]
which are not only able to bind to langerin but also to other C-
type lectins such as Dendritic Cell-Specific Intercellular
adhesion molecule-3-Grabbing Non-integrin (DC-SIGN)
and Mannose Binding Protein.[22a, 24] Recently, we reported
a specific, glycomimetic langerin ligand comprised of tosy-
lated glucosamine (Glc2NTs, Figure 1 B), which showed
submillimolar affinity (KD = 0.46 mM).
[23] For the rational
design of defined molecular systems that present Glc2NTs
ligands in an arrangement allowing chelate-enhanced binding
we constructed scaffolds composed of complexes formed by
Watson–Crick hybridization of a 39 nucleotide (nt) long DNA
template strand with three 13 nt peptide nucleic acid (PNA)
strands (Figure 1D). In spite of the rather small length, PNA
provides sufficient affinity to maintain integrity at nanomolar
concentrations (Tables S1, S2).[25] Two of the PNA strands
carry the ligand, which was installed via 1,4 addition of
thiolated PNA to maleimide-functionalized Glc2NTs or
TriGlc2NTs (Figure 1B, C). After hybridization with the
DNA template the sugar residues were spaced 5–32 nt
distances apart, corresponding to 16–104 c, based on the
structure of the DNA-PNA helical structure (Table S1, S2).[26]
Binding to trimeric langerin ECD (hereafter named only
ECD) was determined by a previously published 19F-NMR
reporter displacement assay.[27] As expected, a high affinity
was obtained for complex Biv-Glc2NTs-13, which arranges
the ligands in the 42 c distance between the CRDs of the
langerin ECD (Figure 2). The IC50 of 23: 2 mM revealed
a substantial, 16-fold bivalency enhancement over Glc2NTs
(IC50 = 368 mM). Given that a 25 mM concentration of binding
sites was required in the NMR experiments, this IC50
approaches the assay limit and the “true” IC50 may therefore
be lower (vide infra). However, within the error of measure-
ments the distance-affinity profile (Figure 2) appeared rather
shallow with similar IC50 values for complexes presenting the
Glc2NTs ligands in a 16–49 c range. A noteworthy observa-
tion is the high langerin affinity of complexes such as Biv-
Glc2NTs-05 that present the ligands in a distance too small (,
23 c) to allow bridging of two langerin CRDs. Control
measurements showed that the affinity loss observed for
interactions with monomeric langerin CRD was substantially
higher for Biv-Glc2NTs-13 than for Biv-Glc2NTs-05 (IC50
(ECD)/ IC50 (CRD) = 5.2: 0.1 for Biv-Glc2NTs-13 vs. 1.7:
1.0 for Biv-Glc2NTs-05). We inferred: binding interactions
provided by the 5 nucleotide long spacer in Biv-Glc2NTs-05
may be enhanced by statistical rebinding, which seems facile
for langerinQs solvent exposed carbohydrate binding sites[27]
on the flat protein surface.
The systemQs amenability to statistical rebinding guided us
to a rational design of high affinity langerin binders. Recent
investigations showed that the affinity increase that can be
obtained by chelate-type multivalent interactions critically
depends on the strength of the monovalent interaction.[17] The
stronger the interactions between individual receptor-ligand
pairs, the higher the affinity gain provided by the chelate
effect. Assuming that statistical rebinding will provide an
efficient means to foster the interactions with a langerin CRD
and amplify the chelate-effect we attached the trivalent
glycocluster TriGlc2NTs to PNA (Figure 1C). Though at the
concentration limit, the 19F-NMR reporter assay showed that
trivalent TriGlc2NTs had a 30: 7-fold lower IC50 than the
monovalent Glc2NTs, confirming that statistical rebinding
can confer enhancement of langerin affinity (Table S3).
The distance-affinity landscape suggests Biv-Glc2NTs-13
as the most efficient binder of the Biv-Glc2NTs series
(Figure 2). However, given the error of the measurement
such a claim is not justified. For validation, we took recourse
to a surface plasmon resonance (SPR) assay (vide infra) that
provided an improved IC50 limit of only 250 nM (compared to
12.5 mM for 19F-NMR assay). The SPR assay uses a multi-
valent mannose-functionalized polymer as a competitive
langerin ligand. Of note, the avidity of this ligand is much
higher (SPR: KD = 1.5 mM) than the affinity of the competing
monovalent ligand used in the 19F-NMR assay (19F-NMR:
KD = 8 mM). To obtain a conservative estimate of the SEM,
the SPR signal was measured after incubating langerin
(500 nM) with the ligands at a single concentration (10 mM)
in three entirely independent replicates (Table S4, Figure S6).
An Anova test (Suppl. Inf. page S22) confirmed that the
determined differences in inhibition of the langerin—man-
nose-PAA interaction are statistically significant and revealed
the superior inhibitory potency of Biv-Glc2NTs-13.
To evaluate binding of avidity-improved constructs, we
used the SPR assay. The bivalent presentation of the
TriGlc2NTs ligand afforded a remarkable affinity enhance-
ment (Table 1). The net gain of affinity improved from IC50 =
347: 11 mM for the monovalent Glc2NTs to IC50 = 0.3:
0.02 mM for the bivalent presentation of TriGlc2NTs. Com-
plex Biv-TriGlc2NTs-13 provided a 102-fold (168: 13) higher
affinity than the TriGlc2NTs sugar and a 103 (1156: 114)
times higher affinity than the free Glc2NTs ligand. The
distance-affinity profile revealed a remarkably high affinity of
complex Biv-TriGlc2NTs-07, which arranges the ligands in
a distance (23 c) that appears to penalize bridging of two
binding sites. However, given the slightly extended linker
Figure 2. Distance-dependent binding of bivalent Glc2NTs-PNA-DNA
complexes to the langerin ECD assessed by a 19F NMR assay. IC50
values below the vertical dashed line (= IC50 (Glc2NTs)/2) can be due
to bivalency-enhanced interactions. Grey squares mark values for
binding of the langerin CRD. Conditions: complexes incubated at
varied concentration with langerin (50 mM or 25 mM) and 0.1 mM 19F-
marked reporter ligand in 25 mM Tris/HEPES with 10% DMSO, 10%
D2O, 150 mM NaCl, 0.05 mM TFA and 5 mM CaCl2 at pH 7.8 and




21018 www.angewandte.org T 2020 The Authors. Published by Wiley-VCH GmbH Angew. Chem. Int. Ed. 2020, 59, 21016 – 21022
length of TriGlc2NTs, we believe that statistical rebinding (of
a hexavalent ligand) can contribute. According to an alter-
native explanation, small linkers could induce langerin
dimerization. However, this seems unlikely given the low
protein concentration (500 nM) used. Cross-linking should
become more likely with low affinity ligands such as Glc2NTs
(rather than TriGlc2NTs). However, 19F-NMR experiments
with Biv-Glc2NTs-07 did not reveal the existence of species
with rotational diffusion indicative of langerin dimers.
It is instructive to compare the magnitude of the chelate-
induced binding enhancements. A graphical presentation of
the distance dependence of the relative inhibitory potency
illustrates that the TriGlc2NTs ligand amplifies the distance-
affinity response of the bivalent display (Figure 3). Bivalent
versus unconjugated presentation of TriGlc2NTs afforded an
up to 102-fold (168: 13) avidity enhancement, whereas the
weaker ligand Glc2NTs allowed only 101-fold (22: 2) stron-
ger binding. We conclude that statistical rebinding can be
exploited to increase the chelate effect in the same way that
a higher monovalent ligand affinity can be utilized to increase
the avidity of a multivalent binding agent.
Next, we evaluated binding and internalization of the
avidity-enhanced assemblies by langerin-expressing cells.
Displays presenting the Glc2NTs and TriGlc2N2Ts ligands
in 42 c distance were assembled by using Cy5-labeled DNA
templates and incubated with Raji cells at 660 nM concen-
tration. Flow cytometry measurements revealed that Biv-
TriGlc2NTs-13 selectively targeted langerin-expressing Raji
cells (Figure 4 B). The mean fluorescence intensity of cells
expressing langerin was 9 times higher than of wild-type Raji
cells (Figure 4C). With the lower affinity ligands Biv-
Glc2NTs-13 under identical conditions, staining was weaker
and langerin+ Raji cells showed only a 4 times higher
fluorescence intensity than wild-type Raji cells. Fluorescence
microscopic analysis confirmed cell uptake of the bivalent
probe (Figure S9). Targeting was specific for langerin+ cells.
Cells expressing DC-SIGN (a C-type lectin also binding
mannose and fucose type carbohydrates) were not stained.
Furthermore, addition of the strong canonical langerin
inhibitor mannan prevented staining. As a further control,
cells were incubated with a ligand-free DNA-PNA complex.
We concluded that the display systems bind to the cells
canonically via the langerin receptor and the PNA-DNA
scaffold does not bind unspecifically.
High affinity probes can reduce unspecific binding as they
allow for the use of decreased probe concentrations, which
eliminates the need for washing steps. Staining of the Raji
cells was repeated with 66 nM Biv-Glc2NTs-13 and Biv-
TriGlc2NTs-13 without washing after incubation with the
compounds. Indeed, with TriGlc2NTs display Biv-
TriGlc2NTs-13 staining of langerin+ Raji cells succeeded
whereas staining was inefficient with the lower affinity
bivalent probe Biv-Glc2NTs-13 (Figure S8).
Conclusion
Langerin binds a variety of glycans containing mannose,
fucose and sulfated sugars.[21,22c] Given this rather broad
substrate range and considering the multitude of other lectins
such as DC-SIGN, dectin-2 and Mannose Binding Protein
binding similar structures, it has been difficult to selectively
target langerin-expressing cells. Recently, we introduced the
glycomimetic Glc2NTs moiety as a selective ligand and we
demonstrated that attachment of Glc2NTs to liposomes
provided vehicles for targeting of langerin.[23] However,
display systems based on polymers,[28,29] or liposomes carry
tens to thousands of glycan ligands and only a few will be
Table 1: Binding affinities of Glc2NTs, TriGlc2NTs, and the correspond-







Biv-Glc2NTs-07 23 b 52:2
Biv-Glc2NTs-13 42 b 16:1
Biv-Glc2NTs-26 84 b 21:2
Biv-Glc2NTs-32 104 b 40:14
TriGlc2NTs – 50.5:0.5
Mono-TriGlc2NTs – 10.5:2.2
Biv-TriGlc2NTs-07 23 b 0.8:0.1
Biv-TriGlc2NTs-13 42 b 0.3:0.02
Biv-TriGlc2NTs-26 84 b 1.0:0.1
Biv-TriGlc2NTs-32 104 b 1.8:0.7
[a] based on 3.25 b average rise per base pair in a DNA·PNA duplex.
[b] Conditions: ’5 min incubation of complexes with 500 nM langerin in
25 mM HEPES, 150 mM NaCl, 5 mM CaCl2, pH 7.8, 25 8C followed by
determining binding of residual langerin to an a-D-mannose-function-
alized SPR chip.
Figure 3. Distance dependence of relative inhibitory potency (b-value)
of bivalent complexes presenting Glc2NTs (red) or TriGlc2NTs (yellow)
as multiples of the potency of unconjugated Glc2NTs and TriGlc2NTs
ligands, respectively. For example, the maximum value is
IC50(TriGlc2NTs)/IC50(Biv-TriGlc2NTs-13 =168. The dashed lines repre-
sent the valency-corrected b-values based on the number of Glc2NTs
ligands (2 ligands in Biv-Glc2NTs, 6 ligands in Biv-TriGlc2NTs sys-
tems). For example, the maximum valency-corrected b-value is IC50-
(Glc2NTs)/(6 W IC50(Biv-TriGlc2NTs-13)) =193. Error bars consider the
propagation of errors given in Table 1.
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involved in the recognition process. It was the aim of the work
described herein to provide non-polymeric, molecularly well-
defined high affinity langerin binders that require only a few
glycomimetic ligands. Similar attempts have recently been
reported by the Hartmann and Taniguchi groups. Taniguchi
and colleagues arranged 6-sulfo-Galb4(6-sulfo-GlcNAc) dis-
accharides in a C3-symmetric fashion and reported an IC50 =
2.7 mM (compared to IC50 = 3.5 mM for the disaccharide) by
applying an ELISA-type assay with immobilized langerin.[29]
An oligomerized form presenting 33 copies on average
provided for 106-fold improvement of ligand potency. The
influence of surface loading on affinity was not addressed.
Hartmann et al. used artificial 3-arm oligoamides for pre-
sentation of three mannose units. The applied solution-phase
19F-NMR assay (vide supra) showed an IC50 = 44: 6 mM for
the best binding system providing a 102-fold (102: 25) affinity
increase compared to the free ligand.[30] For comparison, the
presentation of the Glc2NTs ligand on the self-assembled
DNA-PNA scaffolds allowed for 103-fold (1156: 114) en-
hancement of the ligand affinity and afforded binders with
nanomolar affinity (IC50 = 0.3 mM).
The high affinity provided by constructs such as Biv-
TriGlc2NTs-13 rely on i) the use of the recently discovered
Glc2NTs ligand that has one order of magnitude higher
affinity for langerin than the canonical mannose ligand, and ii)
a careful design allowing the combination of statistical
rebinding to strengthen the interaction with a single langerin
CRD and chelate-enhanced binding. The alliance of chelation
and statistical rebinding bears resemblance to an approach
reported by Bernardi at al.[31] They targeted DC-SIGN rather
than langerin and arranged small trivalent clusters of
modified mannose bivalently on rigid rod-like scaffolds
comprised of phenylene-ethylene units. It is instructive to
compare the results since both C-type lectin receptors have
rather flat binding surfaces and the monovalent ligands bind
their respective targets with similar affinity. Bernardi report-
ed an IC50 = 5 mM for optimal scaffolds, which based on the
affinity of the free ligand (IC50 = 270 mM) for DC-SIGN
corresponds to a relative potency per ligand = 9. The spatial
screening of langerin with DNA-PNA scaffolds exposed that
bivalent presentation of trivalent clusters can provide for an
order of magnitude enhanced relative potency per ligand =
193, which demonstrates the power of high precision display
from DNA-type scaffolds.
A more detailed analysis points to the factors contributing
to the 1156: 114-times net improvement of affinity (193: 19-
fold improvement of relative affinity per ligand). Statistical
rebinding introduced by the trivalent cluster accounts for
a 2.3: 0.1-fold enhancement of relative potency per ligand
(IC50 (TriGlc2NTs) = 50.5: 0.5 mM vs. IC50 (Glc2NTs) =
347: 11 mM). Attachment of the ligand system to PNA
provides a further 4.8: 1-fold enhancement of relative
potency (IC50 (Mono-TriGlc2NTs) = 10.5: 2.2 mM vs. IC50
(TriGlc2NTs) = 50.5: 0.5 mM). The improved affinity upon
attachment to DNA scaffolds has also been seen in inves-
tigations of other carbohydrate binding proteins.[13b, 15g,32] As
shown in control experiments, unspecific binding of the DNA-
PNA scaffold seems unlikely and we attribute this affinity
increase to steric shielding effects.[33] A comparison of the
monovalent and bivalent display systems exposes the con-
tribution of chelate-enhanced binding. This effect affords
a 17.5: 4.8-fold improvement of relative affinity per ligand
((IC50 (Biv-TriGlc2NTs-13) = 0.3: 0.02 mM vs. IC50 (Mono-
TriGlc2NTs) = 10.5: 2.2 mM) and moves the net affinity to
the nanomolar range. This detailed analysis also points to the
importance of the strength of interactions at individual
binding sites. With the low affinity Glc2NTs ligand chelation
allowed only for a 3.3: 0.2-fold improvement of relative
affinity per ligand, which was increased to 17.5: 4.8-fold with
the higher avidity ligand TriGlc2NTs. Our results support that
the strength of the monovalent receptor-ligand interaction
plays a key role in the affinity gain achievable by bivalent
presentation. However, identifying better monovalent ligands
can be challenging. We present statistical rebinding as an easy
to implement alternative approach to improve chelation-
induced affinity enhancements, with particular importance for
challenging target classes such as lectins. While we focused
Figure 4. Biv-Glc2NTs-13 and Biv-TriGlc2NTs-13 target Raji cells ex-
pressing langerin but not wildtype Raji cells or Raji cells expressing
DC-SIGN. A,B) Histogram presentation of flow cytometry data from
cells incubated with Cy5-labelled Biv-Glc2NTs-13 (A) and Biv-
TriGlc2NTs-13 (B). C) Mean fluorescence intensity (MFI) of cells after
subtraction of autofluorescence background binding/internalization of
Cy5 labelled Biv-Glc2NTs-13, Biv-TriGlc2NTs-13 and ligand-free com-
plex LFC-Cy5. Conditions: Cells were incubated with complexes
(660 nM) in cell media for 45 min at 4 8C and after media exchange,
incubated for 60 min at 37 8C.
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this study on the bivalent presentation of monovalent and
trivalent ligands, it seems possible that higher valencies could
further improve affinity by statistical rebinding. However,
a higher number of clustered ligands may lead to competitive
steric shielding, thereby limiting the positive influence of
ligand quantity on statistical rebinding.
In summary, the strategy of combining chelate-binding
and statistical rebinding of a glycomimetic compound on rigid
PNA-DNA scaffolds provided the most potent, molecularly
defined langerin binder to date, highlighting the usefulness of
scaffolds that allow a precise tuning of ligand-ligand distances.
The high affinity binders were internalized by Raji cells
expressing langerin but not by cells expressing DC-SIGN or
wild-type Raji cells. DNA hybridization provides for facile
attachment of cargo. While we focused on appending
a fluorescent label in this work, we envision other types of
cargo such as vaccination agents or a cytotoxic agent being
similarly attached. Beyond recognition of C-type lectins, we
foresee interesting applications of DNA-type display systems
for the recognition of specific cell types.
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